Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy

Published:2020-08 Issue:1 Volume:1874 Page:188391
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Zhao Yan,Zhang Ya-Ni,Wang Kai-Ting,Chen Lei

Funder

National Research Program of China

state Key project for Infectious Diseases

National Natural Science Foundation of China

National Natural Science Foundation of Shanghai

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference96 articles.

1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

3. Sorafenib in advanced hepatocellular carcinoma;Llovet;N. Engl. J. Med.,2008

4. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy;Kim;J. Gastrointest. Oncol.,2017

5. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models;Tohyama;J. Thyroid. Res.,2014

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotinylated polyaminoacid-based nanoparticles for the targeted delivery of lenvatinib towards hepatocarcinoma;International Journal of Pharmaceutics;2024-09

2. The potential of lenvatinib in breast cancer therapy;Medical Oncology;2024-08-22

3. Tumor-produced immune regulatory factors as a therapeutic target in cancer treatment;Frontiers in Immunology;2024-08-14

4. Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma;Pharmaceuticals;2024-08-11

5. Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells;Oncology Letters;2024-08-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3